AU2015350108B2 - Method for treating cancer - Google Patents

Method for treating cancer Download PDF

Info

Publication number
AU2015350108B2
AU2015350108B2 AU2015350108A AU2015350108A AU2015350108B2 AU 2015350108 B2 AU2015350108 B2 AU 2015350108B2 AU 2015350108 A AU2015350108 A AU 2015350108A AU 2015350108 A AU2015350108 A AU 2015350108A AU 2015350108 B2 AU2015350108 B2 AU 2015350108B2
Authority
AU
Australia
Prior art keywords
amount
compound
salt
hydroxypropyl cellulose
epz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015350108A
Other languages
English (en)
Other versions
AU2015350108A1 (en
Inventor
Heike KEILHACK
Tsukasa Murase
Futoshi SHIKATA
Yuta Suzuki
Brett TRUITT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Epizyme Inc
Original Assignee
Eisai R&D Management Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd, Epizyme Inc filed Critical Eisai R&D Management Co Ltd
Publication of AU2015350108A1 publication Critical patent/AU2015350108A1/en
Application granted granted Critical
Publication of AU2015350108B2 publication Critical patent/AU2015350108B2/en
Priority to AU2021204706A priority Critical patent/AU2021204706B2/en
Priority to AU2024201171A priority patent/AU2024201171A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2015350108A 2014-11-17 2015-11-17 Method for treating cancer Active AU2015350108B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021204706A AU2021204706B2 (en) 2014-11-17 2021-07-06 Method for treating cancer
AU2024201171A AU2024201171A1 (en) 2014-11-17 2024-02-22 Method for treating cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US62/080,985 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US62/166,572 2015-05-26
US201562251903P 2015-11-06 2015-11-06
US62/251,903 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021204706A Division AU2021204706B2 (en) 2014-11-17 2021-07-06 Method for treating cancer

Publications (2)

Publication Number Publication Date
AU2015350108A1 AU2015350108A1 (en) 2017-05-25
AU2015350108B2 true AU2015350108B2 (en) 2021-04-08

Family

ID=56014476

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015350108A Active AU2015350108B2 (en) 2014-11-17 2015-11-17 Method for treating cancer
AU2021204706A Active AU2021204706B2 (en) 2014-11-17 2021-07-06 Method for treating cancer
AU2024201171A Pending AU2024201171A1 (en) 2014-11-17 2024-02-22 Method for treating cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021204706A Active AU2021204706B2 (en) 2014-11-17 2021-07-06 Method for treating cancer
AU2024201171A Pending AU2024201171A1 (en) 2014-11-17 2024-02-22 Method for treating cancer

Country Status (21)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP3220916B1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (3) KR102338802B1 (enExample)
CN (2) CN107249591B (enExample)
AU (3) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
CA (1) CA2967664A1 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX376008B (es) 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
KR20220165809A (ko) 2013-12-06 2022-12-15 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
PL3157527T3 (pl) 2014-06-17 2023-08-07 Epizyme, Inc. Inhibitory ezh2 do leczenia chłoniaka
HUE062159T2 (hu) * 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
MX2018002344A (es) 2015-08-24 2018-07-06 Epizyme Inc Metodo para tratar el cancer.
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
CN110191722B (zh) 2017-01-19 2022-03-01 第一三共株式会社 用于治疗htlv-1相关性脊髓病的药物组合物
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
CA3162315A1 (en) * 2019-12-20 2021-06-24 Marinus Jacobus Verwijs Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138361A1 (en) * 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2013155464A1 (en) * 2012-04-13 2013-10-17 Epizyme, Inc. Combination therapy for treating cancer
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
WO2015195848A1 (en) * 2014-06-17 2015-12-23 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
PL2614369T3 (pl) * 2010-09-10 2016-08-31 Epizyme Inc Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu
EP2663283B1 (en) * 2011-01-14 2017-05-10 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
PL3628670T3 (pl) * 2012-04-13 2023-02-20 Epizyme, Inc. Postać soli dla inhibicji ezh2
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
SI3057962T1 (sl) * 2013-10-16 2024-01-31 Epizyme, Inc. Oblika hidrokloridne soli za ezh2 inhibicijo
AU2014337121A1 (en) * 2013-10-18 2016-04-14 Epizyme, Inc. Method of treating cancer
KR20220165809A (ko) 2013-12-06 2022-12-15 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
JP6890097B2 (ja) * 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
JP2019521988A (ja) * 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138361A1 (en) * 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2013155464A1 (en) * 2012-04-13 2013-10-17 Epizyme, Inc. Combination therapy for treating cancer
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
WO2015195848A1 (en) * 2014-06-17 2015-12-23 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COPELAND, R. A. et al., "EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations", (2014-08-12) *
KNUTSON, S. K. et al., "Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma", Molecular Cancer Therapeutics., (2014), vol. 13, no. 4, pages 842 - 854 *
SANDEEP, N. et al., "Immediate Drug Release Dosage Form: A Review", Journal of Drug Delivery & Therapeutics., (2013), vol. 3, no. 2, pages 155 - 161 *

Also Published As

Publication number Publication date
EP4272742A1 (en) 2023-11-08
AU2015350108A1 (en) 2017-05-25
IL252182A0 (en) 2017-07-31
PL3220916T3 (pl) 2023-08-14
EP3220916A1 (en) 2017-09-27
MX2017006089A (es) 2017-12-11
JP2021073241A (ja) 2021-05-13
IL252182B2 (en) 2023-02-01
US10786511B2 (en) 2020-09-29
IL252182B (en) 2022-10-01
AU2021204706B2 (en) 2023-11-23
PT3220916T (pt) 2023-06-26
NZ731696A (en) 2024-03-22
US20250064822A1 (en) 2025-02-27
MX383484B (es) 2025-03-11
HUE062159T2 (hu) 2023-10-28
US20170360797A1 (en) 2017-12-21
MX2021006734A (es) 2021-07-02
JP2023062189A (ja) 2023-05-02
CA2967664A1 (en) 2016-05-26
US12168014B2 (en) 2024-12-17
DK3220916T3 (da) 2023-06-26
KR20210156840A (ko) 2021-12-27
JP6829684B2 (ja) 2021-02-10
IL296080A (en) 2022-11-01
ES2947819T3 (es) 2023-08-21
EP3220916B1 (en) 2023-04-19
WO2016081523A1 (en) 2016-05-26
IL296080B2 (en) 2023-12-01
FI3220916T3 (fi) 2023-06-19
EP3220916A4 (en) 2018-07-11
IL296080B1 (en) 2023-08-01
US20210060030A1 (en) 2021-03-04
NZ768247A (en) 2024-05-31
AU2021204706A1 (en) 2021-07-29
SG11201703806XA (en) 2017-06-29
JP2017537899A (ja) 2017-12-21
KR102644844B1 (ko) 2024-03-07
IL304252A (en) 2023-09-01
IL304252B1 (en) 2025-11-01
KR102338802B1 (ko) 2021-12-14
CN107249591B (zh) 2024-01-30
JP7485810B2 (ja) 2024-05-16
EA201791095A1 (ru) 2017-10-31
KR20240035908A (ko) 2024-03-18
LT3220916T (lt) 2023-07-25
KR20170103768A (ko) 2017-09-13
AU2024201171A1 (en) 2024-03-14
CN107249591A (zh) 2017-10-13
CN116650500A (zh) 2023-08-29
SI3220916T1 (sl) 2023-09-29
BR112017010166A2 (en) 2018-02-14
IL323396A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
AU2021204706B2 (en) Method for treating cancer
US11642349B2 (en) Method for treating cancer
HK40103478A (en) Epz-6438 for use in a method for treating cancer
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
WO2021231928A1 (en) A method for treating cancer with an oral dosage form of an fgfr4 inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)